The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Sotorasib plus panitumumab for pre-treated non-small cell lung cancer with KRASG12C mutation: A phase 1b study.
 
Corey J. Langer
Honoraria - AstraZeneca; Genentech/Roche; Lilly/ImClone; Merck; Takeda Science Foundation
Consulting or Advisory Role - Abbott Biotherapeutics; ARIAD; AstraZeneca; Bayer/Onyx; Bristol-Myers Squibb; Cancer Support Community; Celgene; Clarient; Clovis Oncology; Genentech/Roche; Gilead Sciences; Lilly/ImClone; Merck; Novocure; Pfizer; Regeneron; Takeda
Research Funding - Advantagene (Inst); Amgen; Ariad (Inst); AstraZeneca; Celgene (Inst); Clovis Oncology (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Incyte; Inovio Pharmaceuticals (Inst); Johnson & Johnson/Janssen; Lilly; Merck (Inst); Stem CentRx (Inst); Trizell (Inst)
Other Relationship - Amgen; Lilly; OncoCyte; Peregrine Pharmaceuticals; Summit Therapeutics; Synta
 
Rachel Galot
Travel, Accommodations, Expenses - MSD; MSD
 
Hans Prenen
Honoraria - Amgen; AstraZeneca; Merck; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Biocartis; cureteq
 
David S. Hong
Stock and Other Ownership Interests - MolecularMatch; OncoResponse; Telperian
Consulting or Advisory Role - 28Bio; Acuta; Adaptimmune; Alkermes; Alphasights; Amgen; AUM Biosciences; Axiom Biotechnologies; Baxter; Bayer; Boxer Capital; Bridgebio; COG; Cor2Ed; Cowen; EcoR1 Capital; Exelixis; Experimental Drug Development Centre (EDDC)/A*STAR; Genentech; Gennao Bio; Gerson Lehrman Group; Gilead Sciences; GroupH; Guidepoint Global; HCW Precision; Immunogen; Incyte; Infinity Pharmaceuticals; Inhibrix Inc; Janssen; Jounce Therapeutics; Liberum; MedaCorp; Medscape; Novartis; Numab; Oncologia Brasil; Pfizer; Pharma Intelligence; Precision Oncology Experimental Therapeutics; Prime Oncology; RAIN; ST Cube; Takeda; Tavistock Life Sciences; Trieza Therapeutics; Turning Point Therapeutics; WebMD; YingLing Pharma; ZIOPHARM Oncology
Research Funding - Abbvie (Inst); Adaptimmune (Inst); Adlai Nortye (Inst); Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol Myers Squibb (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Eisai (Inst); Endeavor BioMedicines (Inst); Erasca, Inc (Inst); F. Hoffmann LaRoche (Inst); Fate Therapeutics (Inst); Genentech (Inst); Genmab (Inst); Ignyta (Inst); Infinity Pharmaceuticals (Inst); Kite, a Gilead company (Inst); Kyowa (Inst); Lilly (Inst); Loxo (Inst); MedImmune (Inst); Merck (Inst); Mirati Therapeutics (Inst); Mologen (Inst); National Cancer Institute (Inst); Navire (Inst); Novartis (Inst); Numab (Inst); Pfizer (Inst); Pyramid Biosciences (Inst); Seagen (Inst); Takeda (Inst); TCR2 Therapeutics (Inst); Teckro (Inst); Turning Point Therapeutics (Inst); VM Pharma (Inst)
Travel, Accommodations, Expenses - AACR; ASCO; Bayer Schering Pharma; CLCC; Genmab; Society for Immunotherapy of Cancer; Telperian
 
Iván Victoria
No Relationships to Disclose
 
Ravi Salgia
No Relationships to Disclose
 
Maxime Chenard-Poirier
Honoraria - Incyte; Pfizer
Consulting or Advisory Role - Eisai; Merck
 
Muhammad Furqan
Consulting or Advisory Role - Abbvie; AstraZeneca/MedImmune; BeiGene; BeiGene; Jazz Pharmaceuticals; Mirati Therapeutics; Novartis; Omega Therapeutics
Speakers' Bureau - Binaytara Foundation - Education Academy
Research Funding - Abbvie (Inst); Abbvie/Stemcentrx (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); BeiGene (Inst); Biothera (Inst); Bristol-Myers Squibb/Celgene (Inst); Celgene (Inst); Checkmate Pharmaceuticals (Inst); Elicio Therapeutics (Inst); Genentech (Inst); Genmab (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Immunocore (Inst); Incyte (Inst); InhibRx (Inst); Jacobus Pharmaceutical Company (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Poseida Therapeutics (Inst); SOPHiA Genetics (Inst)
 
Emily Chan
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Jane Nolte-Hippenmeyer
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Caihong Xia
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Bob T. Li
Research Funding - Ambrx (Inst); Amgen (Inst); AstraZeneca (Inst); Bolt Biotherapeutics (Inst); Daiichi Sankyo (Inst); Hengrui Therapeutics (Inst); Lilly (Inst); MORE Health (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - Karger Publishers - Book royalty; Shanghai Jiao Tong University Press - Book royalty; US62/514,661 (Inst); US62/685,057 (Inst)
Travel, Accommodations, Expenses - Amgen
(OPTIONAL) Uncompensated Relationships - Amgen; AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo; Lilly